HLB Therapeutics Aims to Stage Comeback with RGN-259 Ahead of US Phase 3 Trial
Predicted impact: Low· Actual: −4.2% vs sector, volume 0.4× normal (5 trading days)
Preview of a planned US Phase 3 trial; no new data or timing given.
HLB TherapeuticsHLB테라퓨틱스
115450 · KOSDAQ · ₩115450 · HLB테라퓨틱스
₩2,650▼ ₩45 (1.67%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −16.35%
- Market cap
- ₩251B
- Enterprise value
- ₩276B
- P/E
- —
- P/B
- 1.7×
- Dividend yield
- 0.0%
- ROE
- −12.5%
- Net margin
- −28.0%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.3% from the high
₩1,342Today: ₩2,580 – ₩2,730₩4,160
Returns
- 1W−2.2%
- 1M+33.4%
- 3M+66.6%
- 6M−24.3%
- YTD−7.3%
- 1Y−16.3%
- Volume today
- 401,914
- 0.3× the 20-day average
- Traded today
- ₩1.1B
- Listed shares
- 94,683,294
- EPS (12 months)
- −₩190
- Earnings yield −7.2%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 26 of 100 (50 is a normal day for this stock).
- MomentumFlat33.7% over the last month; the price is below its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
HLB Therapeutics stock overview
HLB Therapeutics (HLB테라퓨틱스, KRX: 115450) is listed on KOSDAQ, in the Retail & Trade sector. The company operates through three core business divisions: bio, cold chain, and electronics. Its shares closed at ₩2,650 on Oct 27, 2026, down 1.67% on the day, giving it a market value of ₩251B.
Key facts
- Market cap
- ₩251B
- Sector
- Retail & Trade
- Latest price change
- −1.67%
- As of
- Oct 27, 2026
- Main business
- The company operates through three core business divisions: bio, cold chain, and electronics.
Quick answers about HLB Therapeutics
- What does HLB Therapeutics do?
- The company operates through three core business divisions: bio, cold chain, and electronics. It was founded to develop and sell embedded graphical user interface software and later diversified into motors, pumps, and transformers for home gas boilers and water heaters, vaccine sales and distribution for cold chain services, and biopharmaceutical drug development. It sells vaccines and pharmaceutical distribution services domestically and exports some motors and pumps, with its electronics production based in a single factory in Chilgok, Gyeongbuk, South Korea.
- What is the market cap of HLB Therapeutics?
- The market capitalisation of HLB Therapeutics was ₩251B at the close on Oct 27, 2026.
- Who are the largest shareholders of HLB Therapeutics?
- According to the latest official filings, the largest reported holders are HLB (20.14%, as of Oct 21, 2026); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.39%, as of Jul 31, 2026); VANGUARD DEVELOPED MARKETS INDEX FUND (0.90%, as of Jun 30, 2026).
- When is the next earnings report from HLB Therapeutics?
- Korean companies rarely announce results dates in advance. Based on when HLB Therapeutics filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own HLB Therapeutics?
- Yes. The National Pension Service held 0.10% of HLB Therapeutics shares as of Dec 31, 2025.
Company profile
The company operates through three core business divisions: bio, cold chain, and electronics. It was founded to develop and sell embedded graphical user interface software and later diversified into motors, pumps, and transformers for home gas boilers and water heaters, vaccine sales and distribution for cold chain services, and biopharmaceutical drug development. It sells vaccines and pharmaceutical distribution services domestically and exports some motors and pumps, with its electronics production based in a single factory in Chilgok, Gyeongbuk, South Korea.
Written by AI from the company's latest annual report.
- Korean name
- HLB테라퓨틱스
- Sector
- Retail & Trade
- Themes
- Biotech (new drugs)
- CEO
- 안기홍
- Founded
- Jun 2000
- Listed
- Mar 2010
- Listed shares
- 94,683,294
- Fiscal year ends
- Month 12
- Website
- -
Similar companies
- Samsung C&T028260 · ₩49T₩301,000+3.08%
- POSCO International047050 · ₩8.8T₩49,850+0.61%
- ISC095340 · ₩3.2T₩151,300+7.61%
- Youngone111770 · ₩3T₩68,100+1.04%
- Dong SUH Companies026960 · ₩2.7T₩27,500+0.73%
- Shinsegae004170 · ₩2.3T₩245,0000.00%
- SK Gas018670 · ₩2.3T₩249,000−0.80%
- Lotte Shopping023530 · ₩2.3T₩81,300−0.12%
Recent news
Recent filings
See all- 5%+ holding reportOct 21, 2026
- Investor relations (IR) eventOct 12, 2026
- 5%+ holding reportOct 2, 2026
- [Corrected] Adjustment of Conversion PriceSep 9, 2026
- Adjustment of Conversion PriceSep 4, 2026
Titles in Korean until English translations are added.
Also known as: HLB Therapeutics / HLB테라퓨틱스 / 115450 / KRX:115450
Source: KRX statistical information